For patients with type 2 diabetes (T2D) who haven’t adequately controlled their blood glucose, taking the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide may benefit from switching to GLP-1 tirzepatide rather than upping their dosage.
CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy to provide direct-to-patient doses of Wegovy for $499 per month. Eligible self-paying patients can also get the $499-per-month price at their local pharmacy. The new formulary change … Read more
Around 1.5 million people a month in Britain are paying privately for weight-loss jabs as demand for the drugs continues to soar, a leading pharmacist has said. Olivier Picard, the head of the National Pharmacy Association (NPA), said the number – much higher than previously thought – was a clear sign of ample stock in … Read more
May 1, 2025 Dataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapies A press release from Illumina announces a collaboration with Ovation.io to create a significant dataset focused on patients treated with GLP-1 therapies. This dataset integrates clinical information with genomic and proteomic insights from 25,000 patients. … Read more
That’s the question researchers aim to answer in a new, first-of-its-kind, clinical trial in North Texas By Bianca Castro • Published April 30, 2025 • Updated on April 30, 2025 at 10:52 pm Researchers in Dallas are investigating the potential of weight loss medications, specifically a drug called tirzepatide, as a novel approach to reducing the risk of breast cancer recurrence in women who are … Read more
Full Frame Growth Partners is a minority investor in California-based Supergut, a company making powdered supplements and bars to boost the GLP-1 hormone. Here’s why its founder and managing partner is investing in the company. Plus, read more about the shift GLP-1 drugs are making in the CPG world.
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge Reuters Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health Yahoo Finance Novo Nordisk announces that CVS Caremark®, the country’s largest PBM, has decided Wegovy® will be the preferred GLP-1 medicine covered for obesity on its template formularies PR Newswire CVS to boost access to … Read more
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, are widely used in the treatment of metabolic disorders, including type 2 diabetes (T2D) and obesity. These medications primarily function by enhancing insulin secretion; however, emerging evidence suggests that the effects extend beyond metabolic regulation. In this issue of the JCI, Farokhnia et al. evaluated the effects … Read more
Keeping up with the GLP-1 area is a full time job by itself. First off, you have the recent development that these drugs are no longer considered to officially be in shortage, which (in theory) closes the regulatory loophole that compounding pharmacies have been using to offer their own versions. And that is already showing … Read more
